Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai to Optimize Area Management, Strengthen Expertise through Marketing System Reorganization: Marketing Chief
Chugai Pharmaceutical aims to build a marketing system that optimizes area management and strengthens expertise, said Susumu Kato, general manager of the Marketing & Sales Division, on February 1. These moves will be taken in response to the development of…
To read the full story
Related Article
- Chugai to File Flurry of Applications in 2017 for New Drugs and Indications Including Emicizumab
February 3, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Chugai Logs Positive Sales in Japan, but Earnings Falter
February 2, 2017
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
BUSINESS
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…